The following is a summary of “Impact of impaired renal function on kinetics of high-sensitive cardiac troponin following ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Outcomes assessed were all-cause mortality, hospitalization for acute myocardial infarction, development of end-stage renal disease, and the occurrence of a doubling in serum creatinine from the ...

Classical symptoms of acute myocardial infarction include sudden chest pain ... obesity, chronic kidney disease, heart failure, excessive alcohol consumption, the abuse of certain drugs (such ...

The following is a summary of “Restrictive or Liberal Blood Transfusion in Patients with Myocardial Infarction and CKD,” ...

Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22; SHARP, Study of Heart And Renal Protection; TARA, Trial of Atorvastatin in Rheumatoid ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Thiazolidinedione use was associated with lower risk for mortality and cardiorenal events among adults with type 2 diabetes and acute kidney disease.

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.